Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Anika Therapeutics Inc(ANIK)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANIK
09/25/2026: ANIK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Anika Therapeutics is a medical device company focused on joint preservation and regenerative medicine, utilizing a proprietary hyaluronic acid technology platform. The company has a leading position in specific viscosupplementation markets, providing pain relief for osteoarthritis. Its primary growth strategy involves expanding its surgical portfolio and commercial reach, bolstered by past strategic acquisitions. However, Anika faces significant risks from larger, well-capitalized competitors, regulatory hurdles, and potential pricing pressure in the healthcare sector. The stock may suit growth-oriented investors interested in medical technology, though it requires monitoring for successful execution in new product segments and consistent revenue scaling in its competitive orthopedic business.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company is transitioning through product portfolio expansion but faces growth execution hurdles. |
| Momentum investor | Weak fit | The stock often lacks the consistent upward trend required for pure momentum strategies. |
| Value investor | Mixed fit | Valuation fluctuates based on pipeline potential rather than established cash flow stability. |
| Dividend investor | Weak fit | Anika does not pay a dividend and focuses capital on R&D and acquisitions. |
| Low-risk investor | Weak fit | High volatility associated with small-cap biotech/med-tech risk makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is susceptible to large swings based on clinical and regulatory news. |
| Valuation risk | Medium | Price discovery is heavily dependent on future revenue expectations from the pipeline. |
| Competition risk | High | Large incumbents with deep pockets dominate the orthopedic space. |
| Business quality | Medium | The company has a specialized niche but faces scaling challenges. |
| Dividend income | Low / none | Investors should not expect income generation from this equity. |
| Execution risk | Medium / high | Integrating acquisitions and achieving market penetration requires high operational precision. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 13.71% | Avg. Invested days 46 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 272.61M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 93.9K shares | Beta 0.2 | 52 Weeks Range 8.67 - 22.88 | Updated Date 09/27/2026 |
52 Weeks Range 8.67 - 22.88 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Orthobiologics & Joint Health | Injectable HA products like ORTHOVISC and CINGAL for pain management. | The company generates revenue primarily by selling medical devices used in orthopedic procedures. |
| Joint Preservation & Restoration | Surgical implants and tools acquired through Parcus and Arthrosurface. | The company has expanded into surgical repair tools to provide a more comprehensive solution for joint health. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 21.51 | Enterprise Value 260.52M | Price to Sales(TTM) 2.26 |
Enterprise Value 260.52M | Price to Sales(TTM) 2.26 | ||
Enterprise Value to Revenue 2.16 | Enterprise Value to EBITDA 508.83 | Shares Outstanding 13.38M | Shares Floating 11.29M |
Shares Outstanding 13.38M | Shares Floating 11.29M | ||
Percent Insiders 6.4 | Percent Institutions 93.45 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Anika Therapeutics Inc
Exchange NASDAQ | Headquarters Bedford, MA, United States | ||
IPO Launch date 1993-04-29 | President, Principal Financial Officer, CEO & Director Mr. Stephen D. Griffin | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 235 | Website https://www.anika.com |
Full time employees 235 | Website https://www.anika.com | ||
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.